CTIS2023-505000-27-01招募中1 期
A phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML patients (A linked-trial of the CHIP-AML22/Master protocol by the NOPHO-DB-SHIP consortium) - MH22CAQ
Prinses Maxima Centrum voor Kinderoncologie B.V.0 个研究点目标入组 41 人开始时间: 2023年11月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 64（—）
- 性别
- All
入选标准
- •Enrollment on CHIP-AML22/Master, FLT3-ITD+ and wild-type NPM1, Age from 1 month to = 18 years old at initial diagnosis, Karnofsky Performance status of >50% for subjects >16 years of age, and a Lansky performance status score of >50% for subjects =16 years of age, Organ function criteria: a. Adequate Renal Function Defined as: • Calculated eGFR = 50 mL/min/1.73 m2 b. Adequate Liver Function Defined as: • Total or direct (conjugated) bilirubin <1.5 × ULN for age (= 5xULN if related to leukemic involvement), AND • Aspartate transaminase (AST) and alanine transaminase (ALT) <5xULN (<10×ULN if related to leukemic involvement),, Life expectancy: > 6 weeks, Pregnancy test negative within 2 weeks prior to enrollment on the quizartinib linked-trial., Patients must be able to reliably swallow or administer quizartinib by NG tube., Written informed consent/assent for the quizartinib linked trial from patients and/or from parents or legal guardians for minor patients, according to local law and regulations.
排除标准
- •Patients with only extramedullary disease, Uncontrolled or significant cardiovascular disease, including i. Diagnosed or suspected congenital long QT syndrome ii. History of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes); any history of arrhythmia will be discussed with sponsor, the national coordinator and C.I. the prior to subject’s entry into the study. iii. QT interval corrected >450 ms: - QTc interval corrected with Fridericia’s formula (QTcF) for subjects = 6 years of age at the time of enrollment. iv. Left ventricular systolic dysfunction (LVSD), defined as ejection fraction (EF) below 55% during the screening for the CHIP-AML22/Master protocol. v. History of uncontrolled angina pectoris or myocardial infarction within 6 months. vi. History of second (Mobitz II) or third degree heart block (subjects with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker). vii. Heart rate <50 beats/minute on ECG during the screening for the CHIPAML22/ Master protocol (In case, adolescents with a normal sinusoidal rhythm and no evidence of other cardiac dysfunction will be discussed with sponsor, the national coordinator and C.I. the prior to subject’s entry into the study.) viii. Uncontrolled hypertension (e.g., systolic blood pressure and /or diastolic blood pressure that is, on repeated measurement, at or above the 95th percentile for sex, age, and height). ix. History of complete left bundle branch block. x. History of New York Heart Association Class 3 or 4 heart failure., Known history of HIV or active clinically relevant liver disease (e.g., active hepatitis B or active hepatitis C), Underlying GI disease that may affect absorption of study drug, Use of strong or moderate CYP3A inducers will be prohibited throughout the duration of the study. Strong CYP3A4 inhibitors will be allowed with a concomitant dose reduction of quizartinib with the exception during the safety run-in., History of hypersensitivity to any of the study medications or their excipients., Other serious illnesses or medical conditions, that will likely make it impossible to complete treatment according to protocol (e.g., patients who should not be given any of the study medications based on the SmPC), Currently participating in other investigational interventional procedures, if it interferes with any endpoints of the quizartinib trial, Additional exclusion criteria during safety run-in a. Patients with CNS3 disease b. Using strong CYP3A4 inhibitors (If patient can stop using strong CYP3A4 inhibitors, he/she will be allowed to enroll. In such case, no washout is required for the strong CYP3A4 inhibitor)
研究者
相似试验
尚未招募
不适用
QPiAML 2020 studyNL-OMON19921Prinses Máxima Centrum voor Kinderoncologie60
进行中（未招募）
1 期
A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma - N/AMalignant MelanomaMedDRA version: 8.0 Level: VTc Classification code 10025650EUCTR2005-002826-70-GBPfizer Inc., 235 East 42nd Street, New York, 10017, USA215
尚未招募
2 期
Treating congenital ichthyosis with targeted therapy (Secukinumab)CTRI/2022/02/040195Department of Health Research
进行中（未招募）
不适用
A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal AdenocarcinomaAdvanced Gastric/Oesophageal AdenocarcinomaEUCTR2005-005660-86-GBChristie Hospital NHS Trust
已完成
2 期
A phase II, open label, single arm study to assess the efficacy of AZD9291 in patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy(WJOG8815L)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000022076Clinical trial coordinating committee for WJOG8815L investigator-initiated multicenter clinical trial60